Neurotech Pharmaceuticals’ surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). It’s the first therapy for this rare retinal degeneration disorder.
Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Iconic Therapeutics is using Tissue Factor biology to create new treatment for age-related macular degeneration with retinal disease in addition to cancer.